Analyst Price Targets — CRL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:43 am | — | Mizuho Securities | $230.00 | $233.41 | TheFly | Charles River price target raised to $230 from $192 at Mizuho |
| July 9, 2026 10:57 am | — | Morgan Stanley | $260.00 | $223.96 | TheFly | Charles River price target raised to $260 from $220 at Morgan Stanley |
| July 1, 2026 7:56 am | — | BNP Paribas | $250.00 | $226.79 | StreetInsider | Charles River Labs (CRL) PT Raised to $250 at Argus |
| July 1, 2026 7:56 am | — | Bernstein | $250.00 | $226.79 | StreetInsider | Charles River Labs (CRL) PT Raised to $250 at Argus |
| June 17, 2026 10:30 am | — | Morgan Stanley | $220.00 | $184.79 | TheFly | Charles River upgraded to Overweight from Equal Weight at Morgan Stanley |
| May 29, 2026 8:36 am | — | CLSA | $219.00 | $181.34 | TheFly | Charles River upgraded to Outperform from Hold at CLSA |
| May 8, 2026 12:45 pm | Eric Coldwell | Robert W. Baird | $213.00 | $175.56 | TheFly | Charles River price target raised to $213 from $200 at Baird |
| May 8, 2026 11:58 am | — | Evercore ISI | $220.00 | $176.32 | TheFly | Charles River price target raised to $220 from $200 at Evercore ISI |
| May 8, 2026 11:15 am | — | Mizuho Securities | $192.00 | $181.68 | TheFly | Charles River price target raised to $192 from $175 at Mizuho |
| May 8, 2026 10:10 am | Luke Sergott | Barclays | $220.00 | $181.68 | TheFly | Charles River price target raised to $220 from $210 at Barclays |
Latest News for CRL
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer…
The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now, thanks to successful financing, progress on shifting its supply chain, and new leadership. Despite the CRL, ACHV continues to advance. The denial was not drug-related, pointing towards a possible…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.